Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer DrugInvestopedia • 11/20/23
Bristol-Meyers Squibb shares fall as FDA delays blood cancer therapy decisionProactive Investors • 11/20/23
Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatmentMarket Watch • 11/20/23
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple MyelomaBusiness Wire • 11/20/23
Bristol-Myers Squibb Company (BMY) Management Presents at Jefferies London Healthcare Conference (Transcript)Seeking Alpha • 11/16/23
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)Business Wire • 11/16/23
Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid InvestmentThe Motley Fool • 11/14/23
Bristol-Myers Squibb Company (BMY) Management Presents at 2023 UBS BioPharma Conference (Transcript)Seeking Alpha • 11/12/23
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?The Motley Fool • 11/11/23